SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Cosmo Daisey who wrote (1672)1/14/1998 9:55:00 AM
From: Michael Bidder  Read Replies (1) | Respond to of 7041
 
Failure to disclose.

This is serious if stockholders lose money. Boeing is under a class
action law suit for failing to disclose knowledge of production difficulties.

<<...Last Friday, Asensio & Company released a report on charges that Zonagen had filed a fraudulent ImmuMAX patent application and had failed to disclose it had been rejected. Despite this, Zonagen continued to promote ImmuMAX to investors and attempted to sell ImmuMAX rights to several companies including Schering-Plough. Likewise, Zonagen filed a Vasomax patent application despite having made no discovery and the prior existence of extensive phentolamine MED studies and products...>>



To: Cosmo Daisey who wrote (1672)1/14/1998 10:08:00 AM
From: Michael Bidder  Read Replies (2) | Respond to of 7041
 
<<...The application confirms that Vasomax's only active ingredient is unaltered generic phentolamine. It also reveals that Vasomax contains no ingredient that can alter phentolamine's chemistry or its effects on the circulatory system. In fact, 212 mg of Vasomax's total 400 mg tablet is lactose, commonly known as milk sugar...>>

If this is true then Zona has no asset.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News